Microbot Medical Inc.
Microbot Medical Inc. (MBOT) Stock Competitors & Peer Comparison
See (MBOT) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MBOT | $2.55 | +0.79% | 92.8M | -3.98 | -$0.64 | N/A |
| ISRG | $483.12 | +0.42% | 173.2B | 67.47 | $7.16 | N/A |
| BDXA | $59.24 | -2.24% | 53.1B | 21.44 | $2.76 | +2.32% |
| BDX | $176.37 | -1.05% | 50.5B | 34.17 | $5.16 | +2.32% |
| ALC | $87.87 | +0.37% | 43.5B | 39.05 | $2.25 | +0.38% |
| RMD | $279.20 | +2.67% | 40.9B | 29.33 | $9.52 | +0.76% |
| WST | $239.26 | +0.00% | 17.2B | 35.79 | $6.68 | +0.35% |
| HOLX | $67.16 | +0.51% | 15B | 27.87 | $2.41 | N/A |
| COO | $70.87 | +0.25% | 14.1B | 34.24 | $2.07 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.32% |
Stock Comparison
MBOT vs ISRG Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, ISRG has a market cap of 173.2B. Regarding current trading prices, MBOT is priced at $2.55, while ISRG trades at $483.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas ISRG's P/E ratio is 67.47. In terms of profitability, MBOT's ROE is -0.85%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, MBOT is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check ISRG's competition here
MBOT vs BDXA Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, BDXA has a market cap of 53.1B. Regarding current trading prices, MBOT is priced at $2.55, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas BDXA's P/E ratio is 21.44. In terms of profitability, MBOT's ROE is -0.85%, compared to BDXA's ROE of +0.06%. Regarding short-term risk, MBOT is more volatile compared to BDXA. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check BDXA's competition here
MBOT vs BDX Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, BDX has a market cap of 50.5B. Regarding current trading prices, MBOT is priced at $2.55, while BDX trades at $176.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas BDX's P/E ratio is 34.17. In terms of profitability, MBOT's ROE is -0.85%, compared to BDX's ROE of +0.06%. Regarding short-term risk, MBOT is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check BDX's competition here
MBOT vs ALC Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, ALC has a market cap of 43.5B. Regarding current trading prices, MBOT is priced at $2.55, while ALC trades at $87.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas ALC's P/E ratio is 39.05. In terms of profitability, MBOT's ROE is -0.85%, compared to ALC's ROE of +0.05%. Regarding short-term risk, MBOT is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check ALC's competition here
MBOT vs RMD Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, RMD has a market cap of 40.9B. Regarding current trading prices, MBOT is priced at $2.55, while RMD trades at $279.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas RMD's P/E ratio is 29.33. In terms of profitability, MBOT's ROE is -0.85%, compared to RMD's ROE of +0.26%. Regarding short-term risk, MBOT is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check RMD's competition here
MBOT vs WST Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, WST has a market cap of 17.2B. Regarding current trading prices, MBOT is priced at $2.55, while WST trades at $239.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas WST's P/E ratio is 35.79. In terms of profitability, MBOT's ROE is -0.85%, compared to WST's ROE of +0.24%. Regarding short-term risk, MBOT is more volatile compared to WST. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check WST's competition here
MBOT vs HOLX Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, HOLX has a market cap of 15B. Regarding current trading prices, MBOT is priced at $2.55, while HOLX trades at $67.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas HOLX's P/E ratio is 27.87. In terms of profitability, MBOT's ROE is -0.85%, compared to HOLX's ROE of +0.12%. Regarding short-term risk, MBOT is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check HOLX's competition here
MBOT vs COO Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, COO has a market cap of 14.1B. Regarding current trading prices, MBOT is priced at $2.55, while COO trades at $70.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas COO's P/E ratio is 34.24. In terms of profitability, MBOT's ROE is -0.85%, compared to COO's ROE of +0.05%. Regarding short-term risk, MBOT is more volatile compared to COO. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check COO's competition here
MBOT vs BDXB Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, MBOT is priced at $2.55, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas BDXB's P/E ratio is 7.60. In terms of profitability, MBOT's ROE is -0.85%, compared to BDXB's ROE of +0.06%. Regarding short-term risk, MBOT is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check BDXB's competition here
MBOT vs BAX Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, BAX has a market cap of 11.3B. Regarding current trading prices, MBOT is priced at $2.55, while BAX trades at $21.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas BAX's P/E ratio is 84.46. In terms of profitability, MBOT's ROE is -0.85%, compared to BAX's ROE of +0.00%. Regarding short-term risk, MBOT is more volatile compared to BAX. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check BAX's competition here
MBOT vs ATR Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, ATR has a market cap of 9.3B. Regarding current trading prices, MBOT is priced at $2.55, while ATR trades at $141.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas ATR's P/E ratio is 25.84. In terms of profitability, MBOT's ROE is -0.85%, compared to ATR's ROE of +0.15%. Regarding short-term risk, MBOT is less volatile compared to ATR. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check ATR's competition here
MBOT vs MASI Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, MASI has a market cap of 8.3B. Regarding current trading prices, MBOT is priced at $2.55, while MASI trades at $153.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas MASI's P/E ratio is -28.20. In terms of profitability, MBOT's ROE is -0.85%, compared to MASI's ROE of -0.41%. Regarding short-term risk, MBOT is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check MASI's competition here
MBOT vs STVN Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, STVN has a market cap of 6.9B. Regarding current trading prices, MBOT is priced at $2.55, while STVN trades at $25.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas STVN's P/E ratio is 47.49. In terms of profitability, MBOT's ROE is -0.85%, compared to STVN's ROE of +0.09%. Regarding short-term risk, MBOT is less volatile compared to STVN. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check STVN's competition here
MBOT vs RGEN Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, RGEN has a market cap of 6.7B. Regarding current trading prices, MBOT is priced at $2.55, while RGEN trades at $118.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas RGEN's P/E ratio is -475.64. In terms of profitability, MBOT's ROE is -0.85%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, MBOT is more volatile compared to RGEN. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check RGEN's competition here
MBOT vs TFX Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, TFX has a market cap of 5.1B. Regarding current trading prices, MBOT is priced at $2.55, while TFX trades at $115.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas TFX's P/E ratio is 27.00. In terms of profitability, MBOT's ROE is -0.85%, compared to TFX's ROE of +0.04%. Regarding short-term risk, MBOT is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check TFX's competition here
MBOT vs MMSI Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, MMSI has a market cap of 5B. Regarding current trading prices, MBOT is priced at $2.55, while MMSI trades at $84.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas MMSI's P/E ratio is 43.04. In terms of profitability, MBOT's ROE is -0.85%, compared to MMSI's ROE of +0.08%. Regarding short-term risk, MBOT is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check MMSI's competition here
MBOT vs BLCO Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, BLCO has a market cap of 4.8B. Regarding current trading prices, MBOT is priced at $2.55, while BLCO trades at $13.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas BLCO's P/E ratio is -17.31. In terms of profitability, MBOT's ROE is -0.85%, compared to BLCO's ROE of -0.09%. Regarding short-term risk, MBOT is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check BLCO's competition here
MBOT vs HAE Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, MBOT is priced at $2.55, while HAE trades at $74.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas HAE's P/E ratio is 22.59. In terms of profitability, MBOT's ROE is -0.85%, compared to HAE's ROE of +0.18%. Regarding short-term risk, MBOT is more volatile compared to HAE. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check HAE's competition here
MBOT vs ICUI Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, ICUI has a market cap of 3.1B. Regarding current trading prices, MBOT is priced at $2.55, while ICUI trades at $127.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas ICUI's P/E ratio is -33.26. In terms of profitability, MBOT's ROE is -0.85%, compared to ICUI's ROE of -0.05%. Regarding short-term risk, MBOT is more volatile compared to ICUI. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check ICUI's competition here
MBOT vs WRBY Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, WRBY has a market cap of 2.9B. Regarding current trading prices, MBOT is priced at $2.55, while WRBY trades at $23.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas WRBY's P/E ratio is -196.75. In terms of profitability, MBOT's ROE is -0.85%, compared to WRBY's ROE of -0.04%. Regarding short-term risk, MBOT is more volatile compared to WRBY. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check WRBY's competition here
MBOT vs XRAY Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, XRAY has a market cap of 2.8B. Regarding current trading prices, MBOT is priced at $2.55, while XRAY trades at $14.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas XRAY's P/E ratio is -3.20. In terms of profitability, MBOT's ROE is -0.85%, compared to XRAY's ROE of -0.38%. Regarding short-term risk, MBOT is more volatile compared to XRAY. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check XRAY's competition here
MBOT vs NNNN Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, NNNN has a market cap of 1.9B. Regarding current trading prices, MBOT is priced at $2.55, while NNNN trades at $42.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas NNNN's P/E ratio is 856.00. In terms of profitability, MBOT's ROE is -0.85%, compared to NNNN's ROE of +0.14%. Regarding short-term risk, MBOT is more volatile compared to NNNN. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check NNNN's competition here
MBOT vs LMAT Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, MBOT is priced at $2.55, while LMAT trades at $81.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas LMAT's P/E ratio is 41.14. In terms of profitability, MBOT's ROE is -0.85%, compared to LMAT's ROE of +0.14%. Regarding short-term risk, MBOT is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check LMAT's competition here
MBOT vs ATRC Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, ATRC has a market cap of 1.7B. Regarding current trading prices, MBOT is priced at $2.55, while ATRC trades at $34.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas ATRC's P/E ratio is -44.69. In terms of profitability, MBOT's ROE is -0.85%, compared to ATRC's ROE of -0.08%. Regarding short-term risk, MBOT is more volatile compared to ATRC. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check ATRC's competition here
MBOT vs QDEL Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, QDEL has a market cap of 1.5B. Regarding current trading prices, MBOT is priced at $2.55, while QDEL trades at $22.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas QDEL's P/E ratio is -4.36. In terms of profitability, MBOT's ROE is -0.85%, compared to QDEL's ROE of -0.11%. Regarding short-term risk, MBOT is more volatile compared to QDEL. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check QDEL's competition here
MBOT vs AZTA Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, AZTA has a market cap of 1.5B. Regarding current trading prices, MBOT is priced at $2.55, while AZTA trades at $32.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas AZTA's P/E ratio is -9.89. In terms of profitability, MBOT's ROE is -0.85%, compared to AZTA's ROE of -0.04%. Regarding short-term risk, MBOT is more volatile compared to AZTA. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check AZTA's competition here
MBOT vs NVCR Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, NVCR has a market cap of 1.3B. Regarding current trading prices, MBOT is priced at $2.55, while NVCR trades at $11.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas NVCR's P/E ratio is -7.26. In terms of profitability, MBOT's ROE is -0.85%, compared to NVCR's ROE of -0.48%. Regarding short-term risk, MBOT is more volatile compared to NVCR. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check NVCR's competition here
MBOT vs BLFS Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, BLFS has a market cap of 995.2M. Regarding current trading prices, MBOT is priced at $2.55, while BLFS trades at $20.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas BLFS's P/E ratio is -109.50. In terms of profitability, MBOT's ROE is -0.85%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, MBOT is more volatile compared to BLFS. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check BLFS's competition here
MBOT vs PLSE Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, PLSE has a market cap of 992.3M. Regarding current trading prices, MBOT is priced at $2.55, while PLSE trades at $14.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas PLSE's P/E ratio is -14.90. In terms of profitability, MBOT's ROE is -0.85%, compared to PLSE's ROE of -0.71%. Regarding short-term risk, MBOT is more volatile compared to PLSE. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check PLSE's competition here
MBOT vs STAA Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, STAA has a market cap of 879.6M. Regarding current trading prices, MBOT is priced at $2.55, while STAA trades at $17.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas STAA's P/E ratio is -12.33. In terms of profitability, MBOT's ROE is -0.85%, compared to STAA's ROE of -0.18%. Regarding short-term risk, MBOT is more volatile compared to STAA. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check STAA's competition here
MBOT vs ATRI Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, MBOT is priced at $2.55, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas ATRI's P/E ratio is 64.50. In terms of profitability, MBOT's ROE is -0.85%, compared to ATRI's ROE of +0.04%. Regarding short-term risk, MBOT is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check ATRI's competition here
MBOT vs KMTS Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, KMTS has a market cap of 789.7M. Regarding current trading prices, MBOT is priced at $2.55, while KMTS trades at $15.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas KMTS's P/E ratio is -3.00. In terms of profitability, MBOT's ROE is -0.85%, compared to KMTS's ROE of +0.27%. Regarding short-term risk, MBOT is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check KMTS's competition here
MBOT vs ANGO Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, ANGO has a market cap of 347.8M. Regarding current trading prices, MBOT is priced at $2.55, while ANGO trades at $8.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas ANGO's P/E ratio is -10.31. In terms of profitability, MBOT's ROE is -0.85%, compared to ANGO's ROE of -0.18%. Regarding short-term risk, MBOT is more volatile compared to ANGO. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check ANGO's competition here
MBOT vs NYXH Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, NYXH has a market cap of 273.2M. Regarding current trading prices, MBOT is priced at $2.55, while NYXH trades at $7.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas NYXH's P/E ratio is -3.17. In terms of profitability, MBOT's ROE is -0.85%, compared to NYXH's ROE of -0.65%. Regarding short-term risk, MBOT is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check NYXH's competition here
MBOT vs OSUR Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, OSUR has a market cap of 225.1M. Regarding current trading prices, MBOT is priced at $2.55, while OSUR trades at $3.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas OSUR's P/E ratio is -7.17. In terms of profitability, MBOT's ROE is -0.85%, compared to OSUR's ROE of -0.08%. Regarding short-term risk, MBOT is more volatile compared to OSUR. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check OSUR's competition here
MBOT vs SMTI Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, SMTI has a market cap of 214.7M. Regarding current trading prices, MBOT is priced at $2.55, while SMTI trades at $24.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas SMTI's P/E ratio is -18.03. In terms of profitability, MBOT's ROE is -0.85%, compared to SMTI's ROE of -0.29%. Regarding short-term risk, MBOT is more volatile compared to SMTI. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check SMTI's competition here
MBOT vs STXS Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, STXS has a market cap of 200.4M. Regarding current trading prices, MBOT is priced at $2.55, while STXS trades at $2.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas STXS's P/E ratio is -7.16. In terms of profitability, MBOT's ROE is -0.85%, compared to STXS's ROE of -2.17%. Regarding short-term risk, MBOT is less volatile compared to STXS. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check STXS's competition here
MBOT vs UTMD Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, UTMD has a market cap of 178.5M. Regarding current trading prices, MBOT is priced at $2.55, while UTMD trades at $54.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas UTMD's P/E ratio is 14.65. In terms of profitability, MBOT's ROE is -0.85%, compared to UTMD's ROE of +0.11%. Regarding short-term risk, MBOT is more volatile compared to UTMD. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check UTMD's competition here
MBOT vs KRMD Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, KRMD has a market cap of 160.6M. Regarding current trading prices, MBOT is priced at $2.55, while KRMD trades at $3.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas KRMD's P/E ratio is -29.00. In terms of profitability, MBOT's ROE is -0.85%, compared to KRMD's ROE of -0.30%. Regarding short-term risk, MBOT is more volatile compared to KRMD. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check KRMD's competition here
MBOT vs PDEX Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, PDEX has a market cap of 154.4M. Regarding current trading prices, MBOT is priced at $2.55, while PDEX trades at $47.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas PDEX's P/E ratio is 17.16. In terms of profitability, MBOT's ROE is -0.85%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, MBOT is more volatile compared to PDEX. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check PDEX's competition here
MBOT vs INFU Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, INFU has a market cap of 120M. Regarding current trading prices, MBOT is priced at $2.55, while INFU trades at $5.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas INFU's P/E ratio is 38.13. In terms of profitability, MBOT's ROE is -0.85%, compared to INFU's ROE of +0.08%. Regarding short-term risk, MBOT is more volatile compared to INFU. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check INFU's competition here
MBOT vs ZJYL Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, ZJYL has a market cap of 100.2M. Regarding current trading prices, MBOT is priced at $2.55, while ZJYL trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas ZJYL's P/E ratio is 32.01. In terms of profitability, MBOT's ROE is -0.85%, compared to ZJYL's ROE of +0.13%. Regarding short-term risk, MBOT is more volatile compared to ZJYL. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check ZJYL's competition here
MBOT vs ZTEK Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, ZTEK has a market cap of 85.5M. Regarding current trading prices, MBOT is priced at $2.55, while ZTEK trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas ZTEK's P/E ratio is -11.66. In terms of profitability, MBOT's ROE is -0.85%, compared to ZTEK's ROE of -0.59%. Regarding short-term risk, MBOT is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check ZTEK's competition here
MBOT vs AKYA Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, MBOT is priced at $2.55, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas AKYA's P/E ratio is -1.34. In terms of profitability, MBOT's ROE is -0.85%, compared to AKYA's ROE of -5.06%. Regarding short-term risk, MBOT is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check AKYA's competition here
MBOT vs OMIC Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, MBOT is priced at $2.55, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas OMIC's P/E ratio is -0.58. In terms of profitability, MBOT's ROE is -0.85%, compared to OMIC's ROE of -0.58%. Regarding short-term risk, MBOT is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check OMIC's competition here
MBOT vs IGAP Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, MBOT is priced at $2.55, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas IGAP's P/E ratio is -10.52. In terms of profitability, MBOT's ROE is -0.85%, compared to IGAP's ROE of +3.93%. Regarding short-term risk, MBOT is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check IGAP's competition here
MBOT vs DXR Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, DXR has a market cap of 49.1M. Regarding current trading prices, MBOT is priced at $2.55, while DXR trades at $9.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas DXR's P/E ratio is -110.00. In terms of profitability, MBOT's ROE is -0.85%, compared to DXR's ROE of +0.02%. Regarding short-term risk, MBOT is more volatile compared to DXR. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check DXR's competition here
MBOT vs WOK Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, WOK has a market cap of 43.8M. Regarding current trading prices, MBOT is priced at $2.55, while WOK trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas WOK's P/E ratio is -2.87. In terms of profitability, MBOT's ROE is -0.85%, compared to WOK's ROE of -0.30%. Regarding short-term risk, MBOT is more volatile compared to WOK. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check WOK's competition here
MBOT vs POCI Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, POCI has a market cap of 36.1M. Regarding current trading prices, MBOT is priced at $2.55, while POCI trades at $4.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas POCI's P/E ratio is -5.18. In terms of profitability, MBOT's ROE is -0.85%, compared to POCI's ROE of -0.54%. Regarding short-term risk, MBOT is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check POCI's competition here
MBOT vs NEPH Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, NEPH has a market cap of 35.8M. Regarding current trading prices, MBOT is priced at $2.55, while NEPH trades at $3.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas NEPH's P/E ratio is 42.25. In terms of profitability, MBOT's ROE is -0.85%, compared to NEPH's ROE of +0.09%. Regarding short-term risk, MBOT is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check NEPH's competition here
MBOT vs MLSS Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, MLSS has a market cap of 34M. Regarding current trading prices, MBOT is priced at $2.55, while MLSS trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas MLSS's P/E ratio is -7.22. In terms of profitability, MBOT's ROE is -0.85%, compared to MLSS's ROE of -0.83%. Regarding short-term risk, MBOT is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check MLSS's competition here
MBOT vs SDC Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, MBOT is priced at $2.55, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas SDC's P/E ratio is -0.03. In terms of profitability, MBOT's ROE is -0.85%, compared to SDC's ROE of -1.96%. Regarding short-term risk, MBOT is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check SDC's competition here
MBOT vs FEMY Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, FEMY has a market cap of 26.7M. Regarding current trading prices, MBOT is priced at $2.55, while FEMY trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas FEMY's P/E ratio is -0.90. In terms of profitability, MBOT's ROE is -0.85%, compared to FEMY's ROE of -3.92%. Regarding short-term risk, MBOT is more volatile compared to FEMY. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check FEMY's competition here
MBOT vs IVC Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, MBOT is priced at $2.55, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas IVC's P/E ratio is -0.79. In terms of profitability, MBOT's ROE is -0.85%, compared to IVC's ROE of -0.46%. Regarding short-term risk, MBOT is more volatile compared to IVC. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check IVC's competition here
MBOT vs NXGLW Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, NXGLW has a market cap of 24.2M. Regarding current trading prices, MBOT is priced at $2.55, while NXGLW trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas NXGLW's P/E ratio is -0.24. In terms of profitability, MBOT's ROE is -0.85%, compared to NXGLW's ROE of -0.63%. Regarding short-term risk, MBOT is more volatile compared to NXGLW. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check NXGLW's competition here
MBOT vs RVP Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, RVP has a market cap of 22.1M. Regarding current trading prices, MBOT is priced at $2.55, while RVP trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas RVP's P/E ratio is -0.97. In terms of profitability, MBOT's ROE is -0.85%, compared to RVP's ROE of -0.27%. Regarding short-term risk, MBOT is less volatile compared to RVP. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check RVP's competition here
MBOT vs NXGL Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, NXGL has a market cap of 19.7M. Regarding current trading prices, MBOT is priced at $2.55, while NXGL trades at $2.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas NXGL's P/E ratio is -5.71. In terms of profitability, MBOT's ROE is -0.85%, compared to NXGL's ROE of -0.63%. Regarding short-term risk, MBOT is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check NXGL's competition here
MBOT vs HBIO Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, HBIO has a market cap of 19.3M. Regarding current trading prices, MBOT is priced at $2.55, while HBIO trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas HBIO's P/E ratio is -0.33. In terms of profitability, MBOT's ROE is -0.85%, compared to HBIO's ROE of -1.10%. Regarding short-term risk, MBOT is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check HBIO's competition here
MBOT vs MHUA Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, MHUA has a market cap of 12.1M. Regarding current trading prices, MBOT is priced at $2.55, while MHUA trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas MHUA's P/E ratio is 0.95. In terms of profitability, MBOT's ROE is -0.85%, compared to MHUA's ROE of +0.09%. Regarding short-term risk, MBOT is less volatile compared to MHUA. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check MHUA's competition here
MBOT vs EKSO Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, EKSO has a market cap of 9.1M. Regarding current trading prices, MBOT is priced at $2.55, while EKSO trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas EKSO's P/E ratio is -0.54. In terms of profitability, MBOT's ROE is -0.85%, compared to EKSO's ROE of -0.87%. Regarding short-term risk, MBOT is more volatile compared to EKSO. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check EKSO's competition here
MBOT vs LUCY Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, LUCY has a market cap of 8.9M. Regarding current trading prices, MBOT is priced at $2.55, while LUCY trades at $1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas LUCY's P/E ratio is 0.04. In terms of profitability, MBOT's ROE is -0.85%, compared to LUCY's ROE of -0.95%. Regarding short-term risk, MBOT is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check LUCY's competition here
MBOT vs POAI Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, POAI has a market cap of 7.8M. Regarding current trading prices, MBOT is priced at $2.55, while POAI trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas POAI's P/E ratio is -0.53. In terms of profitability, MBOT's ROE is -0.85%, compared to POAI's ROE of -5.91%. Regarding short-term risk, MBOT is more volatile compared to POAI. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check POAI's competition here
MBOT vs NSTG Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, MBOT is priced at $2.55, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas NSTG's P/E ratio is -0.03. In terms of profitability, MBOT's ROE is -0.85%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, MBOT is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check NSTG's competition here
MBOT vs STSS Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, STSS has a market cap of 5M. Regarding current trading prices, MBOT is priced at $2.55, while STSS trades at $4.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas STSS's P/E ratio is N/A. In terms of profitability, MBOT's ROE is -0.85%, compared to STSS's ROE of -0.99%. Regarding short-term risk, MBOT is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check STSS's competition here
MBOT vs GCTK Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, GCTK has a market cap of 3.5M. Regarding current trading prices, MBOT is priced at $2.55, while GCTK trades at $6.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas GCTK's P/E ratio is N/A. In terms of profitability, MBOT's ROE is -0.85%, compared to GCTK's ROE of +3.93%. Regarding short-term risk, MBOT is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check GCTK's competition here
MBOT vs GMVD Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, MBOT is priced at $2.55, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas GMVD's P/E ratio is -0.01. In terms of profitability, MBOT's ROE is -0.85%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, MBOT is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check GMVD's competition here
MBOT vs GMVDW Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, MBOT is priced at $2.55, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas GMVDW's P/E ratio is N/A. In terms of profitability, MBOT's ROE is -0.85%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, MBOT is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check GMVDW's competition here
MBOT vs AVGR Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, MBOT is priced at $2.55, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas AVGR's P/E ratio is -0.05. In terms of profitability, MBOT's ROE is -0.85%, compared to AVGR's ROE of -54.25%. Regarding short-term risk, MBOT is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check AVGR's competition here
MBOT vs LUCYW Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, LUCYW has a market cap of 150.2K. Regarding current trading prices, MBOT is priced at $2.55, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas LUCYW's P/E ratio is N/A. In terms of profitability, MBOT's ROE is -0.85%, compared to LUCYW's ROE of -0.95%. Regarding short-term risk, MBOT is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for MBOT.Check LUCYW's competition here
MBOT vs HRC Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, HRC has a market cap of 0. Regarding current trading prices, MBOT is priced at $2.55, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas HRC's P/E ratio is 41.92. In terms of profitability, MBOT's ROE is -0.85%, compared to HRC's ROE of +0.14%. Regarding short-term risk, MBOT is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check HRC's competition here
MBOT vs APR Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, APR has a market cap of 0. Regarding current trading prices, MBOT is priced at $2.55, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas APR's P/E ratio is 22.59. In terms of profitability, MBOT's ROE is -0.85%, compared to APR's ROE of +9.81%. Regarding short-term risk, MBOT is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check APR's competition here
MBOT vs ATRS Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, MBOT is priced at $2.55, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas ATRS's P/E ratio is 14.95. In terms of profitability, MBOT's ROE is -0.85%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, MBOT is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check ATRS's competition here
MBOT vs IIN Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, IIN has a market cap of 0. Regarding current trading prices, MBOT is priced at $2.55, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas IIN's P/E ratio is 226.45. In terms of profitability, MBOT's ROE is -0.85%, compared to IIN's ROE of -0.00%. Regarding short-term risk, MBOT is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check IIN's competition here
MBOT vs LMNX Comparison August 2025
MBOT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 92.8M. In comparison, LMNX has a market cap of 0. Regarding current trading prices, MBOT is priced at $2.55, while LMNX trades at $36.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -3.98, whereas LMNX's P/E ratio is N/A. In terms of profitability, MBOT's ROE is -0.85%, compared to LMNX's ROE of +0.03%. Regarding short-term risk, MBOT is more volatile compared to LMNX. This indicates potentially higher risk in terms of short-term price fluctuations for MBOT.Check LMNX's competition here